These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 3479046)

  • 21. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin.
    Nau R; Kinzig M; Dreyhaupt T; Kolenda H; Sörgel F; Prange HW
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1849-53. PubMed ID: 7986019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of ofloxacin in healthy subjects and patients with impaired renal function.
    Höffler D; Koeppe P
    Drugs; 1987; 34 Suppl 1():51-5. PubMed ID: 3125032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Absorption, distribution, metabolism and excretion of T-3761, a new quinolone derivative, in experimental animals].
    Minami S; Takahata M; Hayashi T; Kumano K; Ikeda Y; Noumi T; Takagi S; Oogake N; Tsuneda R; Maehana J
    Jpn J Antibiot; 1995 May; 48(5):626-42. PubMed ID: 7637197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
    Pedersen SS; Jensen T; Hvidberg EF
    J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of crystalluria and estimation of renal parameters after oral and intravenous ofloxacin as compared to placebo in healthy volunteers.
    Verho M; Malerczyk V; Grötsch H; Lorenz H
    Drugs Exp Clin Res; 1988; 14(8):539-45. PubMed ID: 2907877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diffusion of oral ofloxacin (HOE 280) into human prostatic tissue: assessment by an improved high-performance liquid chromatographic method.
    Claes R; Dusart Y; Dupont JC; Jeanbaptiste B; Podoor M; Douchamps J
    Infection; 1986; 14 Suppl 4():S263-5. PubMed ID: 3469159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of ofloxacin in broiler chicken.
    Kalaiselvi L; Sriranjani D; Ramesh S; Sriram P; Mathuram LN
    J Vet Pharmacol Ther; 2006 Jun; 29(3):185-9. PubMed ID: 16669862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic profile of ITF 296 in rats and dogs.
    Monzani MV; Coltro G; Jiritano L; Sala A
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S67-71. PubMed ID: 8839229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers.
    Yuk JH; Nightingale CH; Quintiliani R; Sweeney KR
    Antimicrob Agents Chemother; 1991 Feb; 35(2):384-6. PubMed ID: 2024973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.
    Mojaverian P; Radwanski E; Affrime MB; Cayen MN; Lin CC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2758-62. PubMed ID: 7695258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinolone pharmacokinetics and metabolism.
    Lode H; Höffken G; Boeckk M; Deppermann N; Borner K; Koeppe P
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():41-9. PubMed ID: 2124212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of ofloxacin. An overview.
    Flor S
    Am J Med; 1989 Dec; 87(6C):24S-30S. PubMed ID: 2603892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure.
    White LO; MacGowan AP; Lovering AM; Reeves DS; Mackay IG
    Drugs; 1987; 34 Suppl 1():56-61. PubMed ID: 3481329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enantioselective disposition of ofloxacin in humans.
    Okazaki O; Kojima C; Hakusui H; Nakashima M
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2106-9. PubMed ID: 1759834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
    Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
    Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of intravenous and oral 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride in the dog as a function of dose and characterization of metabolites.
    Garrett ER; Van Peer A
    J Pharm Sci; 1983 Sep; 72(9):1045-57. PubMed ID: 6631692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients.
    Cundy KC; Barditch-Crovo P; Petty BG; Ruby A; Redpath M; Jaffe HS; Lietman PS
    Antimicrob Agents Chemother; 1999 Feb; 43(2):271-7. PubMed ID: 9925517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.